| Literature DB >> 23818944 |
Huai-Hsuan Tseng1, Sue-Huei Chen, Chih-Min Liu, Oliver Howes, Yu-Lien Huang, Ming H Hsieh, Chen-Chung Liu, Jia-Chi Shan, Yi-Ting Lin, Hai-Gwo Hwu.
Abstract
BACKGROUND: Patients with schizophrenia perform significantly worse on emotion recognition tasks than healthy participants across several sensory modalities. Emotion recognition abilities are correlated with the severity of clinical symptoms, particularly negative symptoms. However, the relationships between specific deficits of emotion recognition across sensory modalities and the presentation of psychotic symptoms remain unclear. The current study aims to explore how emotion recognition ability across modalities and neurocognitive function correlate with clusters of psychotic symptoms in patients with schizophrenia.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23818944 PMCID: PMC3688591 DOI: 10.1371/journal.pone.0066571
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic background and cognitive capacity of patients with schizophrenia and healthy participants.
| Schizophrenia ( | Control ( |
| |
|
| |||
| Gender – no. | M/F :51/60 | M/F : 29/41 | 0.36 |
| Current age – years | 38.23±10.13 | 36.26±11.34 | 1.21 |
| Education – years | 15.89±3.43 | 13.45±10.0 | − 5.38 |
|
| |||
| Estimated VIQ | 94.58±16.91 | 109.97±15.34 | − 6.87 |
| Estimated PIQ | 89.55±19.32 | 112.30±16.23 | − 8.19 |
| Estimated FIQ | 92.48±16.33 | 109.55±18.34 | − 8.51 |
| Working Memory Index (WMI) | 96.11±13.87 | 109.88±14.80 | − 7.61 |
|
| |||
| Age of Onset | 24.81±8.18 | – | – |
| Duration of illness | 13.84±9.74 | – | – |
|
| |||
|
| – | – | |
| WCST Total errors | 0.60±1.21 | – | – |
| WCST perseveration errors | 0.74±1.44 | – | – |
| WCST conceptual responses | −0.57±1.16 | – | – |
| CPT d’ | −0.71±1.29 | – | – |
| CPT beta | −0.32±1.57 | – | – |
p<0.001; using Independent t test for continuous variables; Pearson’s chi-square test for categorical variables.
Clinical symptom ratings in patients with schizophrenia by PANSS and dimension scores.
| PANSS total scores, scale scores and dimensional scores in patients with schizophrenia (n = 92/111) | |
| Total PANSS Scores | 55.60±15.66 |
| Positive Scale | 11.91±4.43 |
| Negative Scale | 14.67±5.85 |
| General Scale | 25.33±7.88 |
| Supplement Scale | 3.69±1.39 |
|
| |
| Delusion/Hallucination | 8.58±4.52 |
| Negative Symptoms | 17.37±6.54 |
| Disorganized thought | 11.64±4.11 |
| Hostility/excitement | 6.40±2.73 |
Current medication in Patients with Schizophrenia (n = 111).
| Medication Name | Number of patients | Range of dosage (mg) | Average dosage (mg) | |
|
| ||||
| Amisulpride | 9 | 200–1200 | 522.22 | per day |
| Aripiprazole | 6 | 7.5–30 | 17.50 | per day |
| Chlorpromazine | 2 | 50–100 | 75.00 | per day |
| Clozapine | 21 | 75–500 | 292.50 | per day |
| Flupentixol | 1 | 5–5 | 5.00 | per day |
| Haloperidol | 7 | 5–20 | 12.14 | per day |
| Olanzapine | 18 | 2.5–30 | 15.42 | per day |
| Quetiapine | 7 | 25–700 | 360.71 | per day |
| Risperidone | 22 | 1–9 | 3.82 | per day |
| Sulpiride | 16 | 200–1000 | 440.63 | per day |
| Trifluoperazine | 1 | 30 | 30.00 | per day |
| Ziprasidone | 3 | 80–160 | 133.33 | per day |
| Zotepine | 6 | 25–300 | 195.83 | per day |
|
| ||||
| Fluphenazine decanoate | 2 | 6.25–12.5 | 9.38 | per week |
| Flupentixol | 4 | 5–20 | 10.83 | per week |
| Risperidone | 4 | 5–12.5 | 10.63 | per week |
|
| ||||
| Bupropion | 1 | 150–150 | 150.00 | per day |
| Fluoxetine | 6 | 20–60 | 31.67 | per day |
| Fluvoxamine | 3 | 50–100 | 83.33 | per day |
| Mirtazapine | 1 | 30 | 30.00 | per day |
| Moclobemide | 1 | 150 | 150.00 | per day |
| Sertraline | 5 | 50–50 | 50.00 | per day |
| Trazodone | 2 | 50–50 | 50.00 | per day |
| Venlafaxine | 2 | 150–150 | 150.00 | per day |
|
| ||||
| Valproic Acid | 4 | 500–1000 | 750.00 | per day |
ANCOVA for the differences of emotion recognition ability between patients with schizophrenia and healthy participants.
| Schizophrenia ( | Control ( |
| Effect size |
| |
|
| |||||
| Overall | 0.67±0.13 | 0.79±0.08 | 14.16 | 1.11 | <0.001 |
| Facial | 0.68±0.13 | 0.77±0.08 | 6.69 | 0.83 | 0.01 |
| Voice | 0.66±0.16 | 0.81±0.10 | 15.78 | 1.12 | <0.001 |
|
| |||||
| Happy | 0.79±0.15 | 0.89±0.09 | 8.97 | 0.55 | 0.03 |
| Sad | 0.71±0.18 | 0.84±0.12 | 8.00 | 0.84 | 0.02 |
| Angry | 0.67±0.15 | 0.74±0.12 | 4.87 | 0.52 | 0.07 |
| Fearful | 0.52±0.23 | 0.70±0.16 | 14.74 | 0.91 | 0.001 |
p<0.10;
p<0.05;
p<0.01;
p<0.001.
Effect size was the standardized mean difference between groups (Cohen’s d).
Correlations between emotion recognition and clinical symptoms (n = 92).
| Overall | Faces | Prosodic | Happy | Sad | Anger | fear | |
| PANSS | −.21 | −.11 | −.25 | −.33 | −.16 | −.04 | −.13 |
| NegativeSymptoms | −.21 | −.15 | −.22 | −.18 | −.19 | −.07 | −.17 |
| Delusion/Hallucination | −.09 | −.05 | −.11 | −.27 | −.13 | .05 | .02 |
| DisorganizedThought | −.15 | −.05 | −.21 | −.27 | −.09 | −.05 | −.08 |
| Excitement/Hostility | −.12 | −.04 | −.17 | −.17 | −.07 | .02 | −.12 |
p<0.05;
p<0.01; using Pearson’s correlation coefficient r.